Weather on Other Worlds. II. Survey Results: Spots Are Ubiquitous on L and T Dwarfs

We present results from the "Weather on Other Worlds" Spitzer Exploration Science program to investigate photometric variability in L and T dwarfs, usually attributed to patchy clouds. We surveyed 44 L3-T8 dwarfs, spanning a range of $J-K_s$ colors and surface gravities. We find that 14/23 (61%; 95% confidence interval: 41%-78%) of our single L3-L9.5 dwarfs are variable with peak-to-peak amplitudes between 0.2% and 1.5%, and 5/16 (31%; 95% confidence interval: 14%-56%) of our single T0-T8 dwarfs are variable with amplitudes between 0.8% and 4.6%. After correcting for sensitivity, we find that 80% (95% confidence interval: 53%-100%) of L dwarfs vary by >0.2%, and 36% (95% confidence interval: 19%-52%) of T dwarfs vary by >0.4%. Given viewing geometry considerations, we conclude that photospheric heterogeneities causing >0.2% 3-5-micron flux variations are present on virtually all L dwarfs, and probably on most T dwarfs. A third of L dwarf variables show irregular light curves, indicating that L dwarfs may have multiple spots that evolve over a single rotation. Also, approximately a third of the periodicities are on time scales >10 h, suggesting that slowly-rotating brown dwarfs may be common. We observe an increase in the maximum amplitudes over the entire spectral type range, revealing a potential for greater temperature contrasts in T dwarfs than in L dwarfs. We find a tentative association (92% confidence) between low surface gravity and high-amplitude variability among L3-L5.5 dwarfs. Although we can not confirm whether lower gravity is also correlated with a higher incidence of variables, the result is promising for the characterization of directly imaged young extrasolar planets through variability.Comment: 42 pages, 11 figures, 2 tables, accepted by Ap

THE TRANSFORMATION OF TRADITIONAL FOLKLORE INTO ANIMATION: IMPACT ON TODAY’S SOCIETY

Abstract As most of the local folklores are not properly documented, the move to transform local folklore into animation is indeed a good news. However, whether the transformation of the folklore into animation maintains its originality in terms of certain important elements, remain unknown. This matter can become an issue in the future, especially among the community in which the folklore belongs to. Therefore, the objective of this study is to analyze the original and the animated versions, in terms of theme, plot, main cast, setting, and values, particularly among the local folklores in the state of Sarawak (East of Malaysia). This study uses qualitative descriptive method in order to examine the folklores. Three animated folklores from Sarawak namely ‘Apai Saloi Hunting’, ‘The Legend of Santubong’ and ‘Commander of Mount Sadok’ were used as prime sources of the study. Data were also collected from people’s statement, written documents, historical heritage, and information from the internet. The results of the study revealed that all the three folklores have at least 95% of similarity between the original version and the animated version. The present study also provides information about the impact and contribution of animated folklore toward the society. It is hoped that more local folklores will be transformed into animated version by maintaining its originality, so that the intangible cultural heritage is being preserved and protected. Keywords: Folklore, Transformation, Animation, Impac

[F-18]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats

Statins are 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors that are widely used to prevent cardiovascular diseases. However, a series of pleiotropic mechanisms have been associated with statins, particularly with atorvastatin. Therefore, the assessment of [F-18]atorvastatin kinetics with positron emission tomography (PET) may elucidate the mechanism of action of statins and the impact of sexual dimorphism, which is one of the most debated interindividual variations influencing the therapeutic efficacy. [F-18]Atorvastatin was synthesized via a previously optimized F-18-deoxyfluorination strategy, used for preclinical PET studies in female and male Wistar rats (n = 7 for both groups), and for subsequent ex vivo biodistribution assessment. PET data were fitted to several pharmacokinetic models, which allowed for estimating relevant kinetic parameters. Both PET imaging and biodistribution studies showed negligible uptake of [F-18]atorvastatin in all tissues compared with the primary target organ (liver), excretory pathways (kidneys and small intestine), and stomach. Uptake of [F-18]atorvastatin was 38 +/- 3% higher in the female liver than in the male liver. The irreversible 2-tissue compartment model showed the best fit to describe [F-18]atorvastatin kinetics in the liver. A strong correlation (R-2 &gt; 0.93) between quantitative Ki (the radiotracer's unidirectional net rate of influx between compartments) and semi-quantitative liver's SUV (standard uptake value), measured between 40 to 90 min, showed potential to use the latter parameter, which circumvents the need for blood sampling as a surrogate of Ki for monitoring [F-18]atorvastatin uptake. Preclinical assays showed faster uptake and clearance for female rats compared to males, seemingly related to a higher efficiency for exchanges between the arterial input and the hepatic tissue. Due to the slow [F-18]atorvastatin kinetics, equilibrium between the liver and plasma concentration was not reached during the time frame studied, making it difficult to obtain sufficient and accurate kinetic information to quantitatively characterize the radiotracer pharmacokinetics over time. Nevertheless, the reported results suggest that the SUV can potentially be used as a simplified measure, provided all scans are performed at the same time point. Preclinical PET-studies with [F-18]atorvastatin showed faster uptake and clearance in female compared to male rats, apparently related to higher efficiency for exchange between arterial blood and hepatic tissue.</p

Elesclomol restores mitochondrial function in genetic models of copper deficiency

© The Author(s), 2018. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Proceedings of the National Academy of Sciences of the United States of America 115 (2018): 8161-8166, doi:10.1073/pnas.1806296115.Copper is an essential cofactor of cytochrome c oxidase (CcO), the terminal enzyme of the mitochondrial respiratory chain. Inherited loss-of-function mutations in several genes encoding proteins required for copper delivery to CcO result in diminished CcO activity and severe pathologic conditions in affected infants. Copper supplementation restores CcO function in patient cells with mutations in two of these genes, COA6 and SCO2, suggesting a potential therapeutic approach. However, direct copper supplementation has not been therapeutically effective in human patients, underscoring the need to identify highly efficient copper transporting pharmacological agents. By using a candidate-based approach, we identified an investigational anticancer drug, elesclomol (ES), that rescues respiratory defects of COA6-deficient yeast cells by increasing mitochondrial copper content and restoring CcO activity. ES also rescues respiratory defects in other yeast mutants of copper metabolism, suggesting a broader applicability. Low nanomolar concentrations of ES reinstate copper-containing subunits of CcO in a zebrafish model of copper deficiency and in a series of copper-deficient mammalian cells, including those derived from a patient with SCO2 mutations. These findings reveal that ES can restore intracellular copper homeostasis by mimicking the function of missing transporters and chaperones of copper, and may have potential in treating human disorders of copper metabolism.This work was supported by National Institutes of Health Awards R01GM111672 (to V.M.G.), R01 DK110195 (to B.-E.K.), and DK 44464 (to J.D.G.); Welch Foundation Grant A-1810 (to V.M.G.); and Canadian Institutes of Health Research Operating Grant MOP 133562 (to S.C.L.)

Mapping Arginase Expression with ¹⁸F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids

Arginase hydrolyzes L-arginine and influences levels of polyamines and nitric oxide. Arginase overexpression is associated with inflammation and tumorigenesis. Thus, radiolabeled arginase inhibitors may be suitable PET tracers for staging arginase-related pathophysiologies. We report the synthesis and evaluation of 2 radiolabeled arginase inhibitors, 18F-FMARS and 18F-FBMARS, developed from α-substituted-2-amino-6-boronohexanoic acid derivatives. Methods: Arylboronic ester-derived precursors were radiolabeled via copper-mediated fluorodeboronation. Binding assays using arginase-expressing PC3 and LNCaP cells were performed. Autoradiography of lung sections from a guinea pig model of asthma overexpressing arginase and dynamic small-animal PET imaging with PC3-xenografted mice evaluated the radiotracers' specific binding and pharmacokinetics. Results:18F-fluorinated compounds were obtained with radiochemical yields of up to 5% (decay-corrected) and an average molar activity of 53 GBq⋅μmol-1 Cell and lung section experiments indicated specific binding that was blocked up to 75% after pretreatment with arginase inhibitors. Small-animal PET studies indicated fast clearance of the radiotracers (7.3 ± 0.6 min), arginase-mediated uptake, and a selective tumor accumulation (SUV, 3.0 ± 0.7). Conclusion: The new 18F-fluorinated arginase inhibitors have the potential to map increased arginase expression related to inflammatory and tumorigenic processes. 18F-FBMARS showed the highest arginase-mediated uptake in PET imaging and a significant difference between uptake in control and arginase-inhibited PC3 xenografted mice. These results encourage further research to examine the suitability of 18F-FBMARS for selecting patients for treatments with arginase inhibitors

Pharmacokinetic Modeling of (R)-[11C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates

(R)-[(11)C]verapamil is a radiotracer widely used for the evaluation of the P-glycoprotein (P-gp) function at the blood-brain barrier (BBB). Several studies have evaluated the pharmacokinetics of (R)-[(11)C]verapamil in rats and humans under different conditions. However, to the best of our knowledge, the pharmacokinetics of (R)-[(11)C]verapamil have not yet been evaluated in nonhuman primates. Our study aims to establish (R)-[(11)C]verapamil as a reference P-gp tracer for comparison of a newly developed P-gp positron emission tomography (PET) tracer in a species close to humans. Therefore, the study assesses the kinetics of (R)-[(11)C]verapamil and evaluates the effect of scan duration and P-gp inhibition on estimated pharmacokinetic parameters. Three nonhuman primates underwent two dynamic 91 min PET scans with arterial blood sampling, one at baseline and another after inhibition of the P-gp function. The (R)-[(11)C]verapamil data were analyzed using 1-tissue compartment model (1-TCM) and 2-tissue compartment model fits using plasma-corrected for polar radio-metabolites or non-corrected for radio-metabolites as an input function and with various scan durations (10, 20, 30, 60, and 91 min). The preferred model was chosen according to the Akaike information criterion and the standard errors (SE %) of the estimated parameters. 1-TCM was selected as the model of choice to analyze the (R)-[(11)C]verapamil data at baseline and after inhibition and for all scan durations tested. The volume of distribution (V(T)) and the efflux constant k(2) estimations were affected by the evaluated scan durations, whereas the influx constant K(1) estimations remained relatively constant. After P-gp inhibition (tariquidar, 8 mg/kg), in a 91 min scan duration, the whole-brain V(T) increased significantly up to 208% (p < 0.001) and K(1) up to 159% (p < 0.001) compared with baseline scans. The k(2) values decreased significantly after P-gp inhibition in all the scan durations except for the 91 min scans. This study suggests the use of K(1), calculated with 1-TCM and using short PET scans (10 to 30 min), as a suitable parameter to measure the P-gp function at the BBB of nonhuman primate

HST Rotational Spectral Mapping of Two L-type Brown Dwarfs: Variability in and out of Water Bands indicates High-altitude Haze Layers

We present time-resolved near-infrared spectroscopy of two L5 dwarfs, 2MASS J18212815+1414010 and 2MASS J15074759−1627386, observed with the Wide Field Camera 3 instrument on the Hubble Space Telescope (HST). We study the wavelength dependence of rotation-modulated flux variations between 1.1 μm and 1.7 μm. We find that the water absorption bands of the two L5 dwarfs at 1.15 μm and 1.4 μm vary at similar amplitudes as the adjacent continuum. This differs from the results of previous HST observations of L/T transition dwarfs, in which the water absorption at 1.4 μm displays variations of about half of the amplitude at other wavelengths. We find that the relative amplitude of flux variability out of the water band with respect to that in the water band shows a increasing trend from the L5 dwarfs toward the early T dwarfs. We utilize the models of Saumon & Marley and find that the observed variability of the L5 dwarfs can be explained by the presence of spatially varying high-altitude haze layers above the condensate clouds. Therefore, our observations show that the heterogeneity of haze layers—the driver of the variability—must be located at very low pressures, where even the water opacity is negligible. In the near future, the rotational spectral mapping technique could be utilized for other atomic and molecular species to probe different pressure levels in the atmospheres of brown dwarfs and exoplanets and uncover both horizontal and vertical cloud structures

EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 50%

Background: Most patients (pts) with NSCLC present with advanced disease at diagnosis. Systemic therapy with platinum-based doublet chemotherapy regimens has been the standard first-line treatment for pts with advanced NSCLC whose tumours do not have EGFR, ALK, or ROS 1 mutations, but there is a need for effective treatments to improve long-term survival. With the recognition that NSCLC tumours express PD-L1, checkpoint inhibitors are being investigated in several clinical trials. There is currently only one PD-1 inhibitor approved as monotherapy in first-line treatment of NSCLC with PD-L1 expression ≥50%. In a phase 1 dose escalation and NSCLC expansion cohort, cemiplimab (REGN2810), a human monoclonal anti-PD-1, has demonstrated antitumour activity with an acceptable safety profile in anti-PD-1 naïve, pre-treated pts with NSCLC. Trial design: This is a randomised (1:1), multicentre, open-label, phase 3 study of cemiplimab versus platinum-based doublet chemotherapy in systemic treatment-naïve pts (≥18 years) with stage IIIB, IIIC or IV squamous or non-squamous NSCLC whose tumours express PD-L1 in ≥ 50% of tumour cells (NCT03088540)